Close

Bristol-Myers Squibb (BMY) Nivolumab Shows Objective Response Rate of 15% in CheckMate -063 Study

October 30, 2014 9:10 AM EDT Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login